China's new coronavirus vaccine Phase 1 clinical trials have achieved positive results

Chinese research team reported in the British medical journal The Lancet on the 22nd that they have conducted a phase 1 clinical trial of a new coronavirus vaccine, which has been shown to be safe and can induce rapid immune response.The clinical trial was conducted by a team led by Academician Chen Wei of the Institute of Bioengineering, Institute of Military Medicine, Academy of Military Sciences, and others. The vaccine used in the trial is an adenovirus vector recombination of the new coronavirus vaccine. The team recruited 108 healthy adult volunteers between the ages of 18 and 60. The volunteers were given different doses of the vaccine in different groups.Within 28 days of vaccination, the vaccine showed good tolerance in different dose groups and did not cause serious adverse reactions, the report said."These results represent an important milestone, " Chen said in a Lancet press release. 'These results represent an important milestone' in showing that the recombinant coronavirus vaccine, adenovirus vector, can induce the production of virus-specific antibodies and T-cells within 14 days.However, Chen Wei also pointed out that to be cautious about the results, the development of new coronavirus vaccine will face unprecedented challenges, and the ability to trigger an immune response does not necessarily mean that the vaccine can protect people from new coronavirus infection, the results "show the new coronavirus vaccine development prospects, but we are still a long way from the vaccine to reach the stage of all people to use."The report says the main limitations of the clinical trial include a small sample size, a shorter trial period, and a lack of randomized control groups, so further trials are needed to verify.According to The Lancet, the development of an effective vaccine is a long-term solution to prevent and control the new crown outbreak, with more than 100 candidate new coronavirus vaccines currently under development worldwide. (Xinhua
)